Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One (European Urology Oncology)

We read with interest a recent paper published in European Urology Oncology by Graham et al [1]. The paper describes `treatment sequence and assess clinical effectiveness of targeted therapy for metastatic renal cell carcinoma (mRCC) patients who received prior immuno-oncology therapy` [1]. Our interest focused on a small set of their patients included in the study--those with chromophobe mRCC, that is, five out of 314 (1.6%) patients (pathology data were available for 298; no further data on those tumors, such as grading or presence of sarcomatoid differentiation, were included).